agenT-797
2019-1305
Phase 1 small_molecule completed
Quick answer
agenT-797 for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at MiNK Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MiNK Therapeutics
- Indication
- Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed